Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Pedro L. Gonzalez"'
Autor:
Bruce M. Jones, Kerry O. Cleveland, Pedro L. Gonzalez, Urania Rappo, Todd Riccobene, Rosie D. Lyles
Publikováno v:
Clinical Infection in Practice, Vol 21, Iss , Pp 100251- (2024)
Objectives: Dalbavancin has potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, and is approved for treatment of acute bacterial skin and skin structure infections (ABSSSI). We describe real-world u
Externí odkaz:
https://doaj.org/article/cc2342e144c14f8da6cd40dcecc7cba9
Autor:
Matias Estaras, Candido Ortiz-Placin, Alba Castillejo-Rufo, Miguel Fernandez-Bermejo, Gerardo Blanco, Jose M. Mateos, Daniel Vara, Pedro L. Gonzalez-Cordero, Sandra Chamizo, Diego Lopez, Adela Rojas, Isabel Jaen, Noelia de Armas, Gines M. Salido, Juan L. Iovanna, Patricia Santofimia-Castaño, Antonio Gonzalez
Publikováno v:
Journal of Physiology and Biochemistry. 79:235-249
We have investigated the effects of melatonin on major pathways related with cellular proliferation and energetic metabolism in pancreatic stellate cells. In the presence of melatonin (1 mM, 100 µM, 10 µM, or 1 µM), decreases in the phosphorylatio
Autor:
Todd Riccobene, John Lock, Rosie D Lyles, Benjamin Georgiades, Michael Nowak, Pedro L Gonzalez, Jenny Park, Urania Rappo
Publikováno v:
Open Forum Infectious Diseases.
Background We assessed the efficacy and safety of dalbavancin, a long-acting lipoglycopeptide with activity against gram-positive pathogens, for treatment of acute bacterial skin and skin structure infections (ABSSSI) in patients with high body mass
Publikováno v:
Lecture Notes on Data Engineering and Communications Technologies ISBN: 9783031279140
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecda1eaffac75bf5c6d498c57a39e849
https://doi.org/10.1007/978-3-031-27915-7_36
https://doi.org/10.1007/978-3-031-27915-7_36
Autor:
Pedro L. Gonzalez, Urania Rappo, Karthik Akinapelli, Jennifer S. McGregor, Sailaja Puttagunta, Michael W. Dunne
Publikováno v:
Infectious Diseases and Therapy. 11:423-434
Publikováno v:
Notas sobre Mamíferos Sudamericanos. :001-007
Autor:
Gregory G. Stone, Mark H. Wilcox, Jean Li Yan, Michal Kantecki, Pedro L Gonzalez, Matthew Dryden
Publikováno v:
Infectious Diseases and Therapy. 11:217-230
INTRODUCTION In three phase III randomized controlled trials, ceftaroline fosamil was shown to be non-inferior to vancomycin plus aztreonam for the treatment of complicated skin and soft tissue infections (cSSTIs). This exploratory analysis evaluated
Autor:
Bruce M Jones, Kerry O Cleveland, Pedro L Gonzalez, Urania Rappo, Todd Riccobene, Rosie D Lyles
Publikováno v:
Open Forum Infectious Diseases. 9
Background Dalbavancin (dalba), a long-acting lipoglycopeptide approved by the US FDA and EMA for acute bacterial skin and skin structure infections (ABSSSI) has potent activity against Gram-positive pathogens including MRSA. We describe the real-wor
Autor:
Karthik Akinapelli, Michael Nowak, Sailaja Puttagunta, Michael W. Dunne, Jennifer C. Nelson, Jennifer S McGregor, Veronica Mas Casullo, Pedro L Gonzalez, Urania Rappo
Publikováno v:
Infectious Diseases and Therapy
Introduction Dalbavancin is a lipoglycopeptide antibiotic approved as a single- and two-dose regimen for adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive organisms. We present nephrotoxicity
Autor:
Natalia Valerievna Zakharova, Adrian G. McNicholl, Maria G. Donday, Nuria Fernandez Moreno, Alfredo J. Lucendo, Horacio Alonso-Galan, Oleg Zaytsev, Rafael Ruíz-Zorrilla López, S A Alekseenko, Jesús Barrio, Javier P. Gisbert, Pedro L. Gonzalez-Cordero, Manuel Castro Fernández, Francis Mégraud, Olga P Nyssen, O. Nunez, Aiman Silkanovna Sarsenbaeva, Ines Modolell, Liudmila Vologzhanina, Colm O'Morain, Oleg Shvetz, Irina Voynovan, José Luis Domínguez-Jiménez, Maria Caldas, Jorge Pérez Lasala, Galina Dmitrivna Fadeenko, Jen Hinojosa, Ángeles Pérez-Aisa, Pilar Varela, Tatiana Ilchishina, Dmitry S. Bordin, Luis Bujanda, Javier Molina-Infante, Javier Alcedo, Cristobal De la Coba, Inmaculada Santaella
Publikováno v:
Clinical Gastroenterology and Hepatology. 18:89-98
Background & Aims Due to the poor eradication rates of standard triple therapy, the addition of bismuth salts has been proposed for first-line eradication of Helicobacter pylori. We assessed the effectiveness and safety of the combination of bismuth